Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding
ผู้เขียน :
Kessuda Khowsroy
,
Jittima Dhitavat
,
Yupa Sabmee
,
Pataramon Laowarakul
,
Jutarat Wattanakitwichai
,
Jiraporn Auetian
,
Kannika Lothong
,
Roongtip Boondao
,
Sarawan Maythaarttaphong
,
Sunee Yaemwong
,
Jean-Louis Excler
,
Supachai Rerks-Ngarm
,
Punnee Pitisuttithum
เผยแพร่วันที่ :
11 ม.ค. 2557
วารสารวิชาการ :
AIDS Research and Human Retroviruses
เล่มที่ :
30
ฉบับที่ :
11
หน้า :
1041-1045
ผู้เผยแพร่ :
Mary Ann Liebert, Inc.
รายละเอียด :
A Phase III community-based HIV vaccine trial using the ALVAC-HIV and AIDSVAX B/E prime-boost regimen (RV144) showed a modest vaccine efficacy of 31.2% against HIV acquisition. Participant's understanding of the trial is a key element of its success. This study aimed to understand participant's expectation and response to the overall results of the trial as well after unblinding. Using an open-ended questionnaire, data were collected from 400 participants who came for the unblinding visit. Fifty-three percent received the vaccine and 47% were placebo recipients. The median age was 30 years (range: 22–37). The observed vaccine efficacy of 31.2% was lower than expected by 67.75% of participants compared to higher than expected (by 6%), as expected (by 11.25%), and those with no expectation (15%). A majority of participants (71.5%) were happy and proud, and indicated that it was a good result. The …
ลิงค์ :